Medtronic

• 8-K

  Filed Sep 17

  MiniMed exchange offer corrects guaranteed-delivery deadline from midnight to 5 p.m. NYC time on the second NYSE trading day after notice execution.

• 10-QQ1 FY2027PositiveRestructuring

  Filed Sep 3

  PulseSelect and Affera/Sphere-9 underpin electrophysiology growth; an extra fiscal week substantially boosted reported sales gains.

  • Revenue$9.8BYoY +13.7%
  • Net income$1.5BYoY +41.3%

• 8-KPositiveEarningsGuidance raised

  Filed Sep 1

  An extra fiscal week boosted broad portfolio growth as FY27 guidance rose; a split-off is preferred for Diabetes.

Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.

Request longer coverage

Company data: Wikidata Q642189